This page is intended as reference information for the general public in the United Kingdom.
What is Velsipity and what is it used for?
Velsipity contains the active substance etrasimod, which belongs to a group of medicines known as sphingosine-1-phosphate receptor modulators.
Velsipity is used in adults and adolescents aged 16 years and older for the treatment of moderately to severely active ulcerative colitis (UC). Ulcerative colitis is an inflammatory disease of the large bowel. Patients with ulcerative colitis will first be given other medicines. If they do not respond well enough or cannot take these medicines, they may be given Velsipity to reduce the signs and symptoms of the disease.
The active substance in Velsipity, etrasimod, prevents lymphocytes (a type of white blood cell) from travelling from the lymph nodes (part of the body’s immune system that contains lymphocytes) into the blood. These lymphocytes are involved in the inflammation that is linked to the development of ulcerative colitis. By reducing the number of lymphocytes circulating in the blood surrounding the large bowel, etrasimod helps to reduce bowel inflammation and the symptoms associated with the disease.
Velsipity can only be obtained with a prescription.
Reference Information
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Velsipity visit the electronic Medicines Compendium (eMC).
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.